Inequities in cancer screenings, care, and outcomes stem primarily from the social determinants of health (SDoH) and the barriers they create. These inequities impact racial and ethnic historically marginalized groups, adolescents and young adults, older people, residents of specific geographic locations (for example, populations from rural areas), members of the LGBTQIA+ community, and individuals with low socioeconomic status, low health literacy, and no or poor health insurance. People from these groups are less likely to receive recommended cancer screenings and more likely to be diagnosed with cancer at later stages, with higher disease burden and poorer outcomes. Nearly half of cancer cases and cancer-related deaths are caused by modifiable risk factors, primarily from SDoH and environmental factors that disproportionately hinder underserved populations. Moreover, members of these groups are less likely to be included in research studies or receive standard of care. However, when these inequities are reduced or eliminated, these individuals often have better outcomes than those not experiencing inequities.
In this OnDemand webcast, expert faculty will discuss the inequities that impact members of historically marginalized groups and the factors that contribute to these disparities. They will review the groups impacted, the role social determinants of health play, and strategies to reduce or eliminate disparities for these communities, leading to better access to screenings, diagnosis, treatment, and outcomes.
At the end of this CME/CE activity, participants should be able to recognize factors contributing to health disparities in the cancer care continuum and their impact on patient care.
Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, nurse navigators, pharmacists, social workers, and case managers specializing in oncology, emergency medicine and/or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Ms. Peterson reports the following financial relationships: Patient Advisory Board: Blue Note Therapeutics and Foundation Medicine, Inc.
Dr. Carthon reports the following financial relationships: Advisory Board: Astellas Pharma US, Inc./Pfizer Inc. and Bristol Myers Squibb Company; Consultant: Gilead Research Scholars Program; Research Support: Alkermes; Astellas Pharma US, Inc.; Bristol Myers Squibb Company; Calithera Biosciences, Inc.; Clovis Oncology; ESSA Pharma; and Immunomedics, Inc.
Dr. Patel reports no financial relationships.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-080-H01-P.
Call us at 877.CME.PROS (877.263.7767).